				7				
J.S. DEPARTMENT OF COMMERCE IPE PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. 00005.001290	APPLICATION 10/573,	ON NO. 378			
PA*	TENT AND TRADEMARK REFERENCES CITED BY Use several sheets if nece	OFFICE 48	APPLICANT Kenya Shitara, et al.					
`			FILING DATE March 24, 2006		ROUP <b>646</b>			
		The Park	U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
				_				
				ļ				
			-					
			70.000.000					
		FC	PREIGN PATENT DOCUMENTS		1			
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TBANSLATION YES/NO/ OR ABSTRACT		
						<del></del>		
		071/50 000			<u></u>			
/I.D./	Russell, et a	I., "Inhibition of th	(Including Author, Title, Date, Pertinent Pages, Etc.) ne mitogenic effects of plasma by a	", <i>Proc</i> .	Natl. Acad	d. Sci., Vol.		
	61, NO. 8 (19	84), pages 2389-2	<b>J</b> 82					
				S				
EXAMINER	/lan Dang/		DATE CONSIDERED 10/23/2007					

Sheet	t <u> </u>	of	1	
-------	------------	----	---	--

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number 10573378 Filing Date 2006-03-24 First Named Inventor Kenya Shitara Art Unit 1647 Examiner Name Ian D. Dang Attorney Docket Number 00005.001290

U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	ate	Name of Pate of cited Docu	entee or Ap <del>plica</del> nt ment	Releva		Lines where ges or Releva	
	1							\			
If you wisl	h to ac	ld additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
						CATION PUBL			Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
/I.D./	1	20060165695		2006-07	-27	Kenya Shitara,	et al.			, , , , , ,	
/I.D./	2	20060263362		2006-11	-23	Atsushi Ochiai,	, et al.				
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Add	button	Add		
				FOREIC	IN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document	or \	where Rel	or Relevant	<b>T</b> 5
/I.D./	1	0 292 656	EP			1988-11-30	Mallinkrodt Inc.				
/I.D.	/2	0 492 552	EP			1992-07-01	Daiichi Seiyaku Co				

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10573378
Filing Date		2006-03-24
First Named Inventor Kenya		a Shitara
Art Unit		1647
Examiner Name Ian D		. Dang
Attorney Docket Number		00005.001290

/I.D./	3	94/04569	wo		1994-03-03	Agricultural & Food Res.			
/I.D./	4	1 661 582	EP		2006-05-31	Kyowa Hakko Kogyo Co., Ltd.			
/I.D./	5	1 505 075	EP		2005-02-09	Kyowa Hakko Kogyo Co., Ltd.			
If you wis	h to a	dd additional Foreign P			· · · · · · · · · · · · · · · · · · ·	ease click the Add buttor			
	·····				RATURE DO		Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							
/I.D./	1	MOHAN, "A simple and efficient scheme for the purification of insulin-like Growth Factor II from human bone matrix extract", Growth Factors, Vol. 2, No. 4 (1990) 267-71							
	2	SCHEVEN, ET AL., "Effects of recombinant human insulin-like Growth Factor I and II (IGF-I/-II) and Growth Hormone (GH) on the", Growth Regulation, Vol. 1, No. 4 (1991) 160-67							
	3	MANES, ET AL., "Functional Epitope Mapping of insulin-like Growth Factor I (IGF-I) by Anti-IGF-I monoclonal antibodies", Endocrinology, Vol. 138, No. 3 (1997) 905-15							
	4	MANES, ET AL., "Physical mapping of human insulin-like growth factor-I using specific monoclonal antibodies", Journal of Endocrinology, Vol. 154, No. 2 (1997) 293-302							
	5	TANAKA, ET AL., "Identification of a family of insulin-like growth factor II secreted by cultured rat", Endocrinology, Vol. 124, No. 2 (1989) 870-77							
$\downarrow$	6	ENJOH, ET AL., "Characterization of new monoclonal antibodies to human insulin-like growth factor-II and their application in Western immunoblot analysis", Journal of Clinical Endocrinology and Metabolism, Vol. 77, No. 2 (1993) 510-17							
If you wish to add additional non-patent literature document citation information please click the Add button Add									

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10573378
Filing Date		2006-03-24
First Named Inventor	Kenya	a Shitara
Art Unit		1647
Examiner Name Ian D		Dang
Attorney Docket Numb	er	00005.001290

EXAMINER SIGNATURE								
Examiner Signature	/lan Dang/	Date Considered	10/23/2007					
*EYAMINER: Initial if reference concidered, whether or not citation is in conformance with MRED 600. Draw line through a								

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10573378
Filing Date		2006-03-24
First Named Inventor Kenya		a Shitara
Art Unit		1647
Examiner Name Ian D		. Dang
Attorney Docket Numb	er	00005.001290

	CERTIFICATION STATEMENT									
Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):										
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).									
OR	OR									
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).									
	See attached ce	rtification statement.								
	Fee set forth in 3	37 CFR 1.17 (p) has been submitte	ed herewith.							
×										
SIGNATURE  A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.										
Sigr	nature	/Lawrence S. Perry/	Date (YYYY-MM-DD)	2007-10-22						
Nan	ne/Print	Lawrence S. Perry	Registration Number	31865						

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**.